Analysts Conflicted on These Healthcare Names: Valneva (VALN) and Supernus Pharmaceuticals (SUPN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Valneva (VALN – Research Report) and Supernus Pharmaceuticals (SUPN – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Valneva (VALN)
In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on Valneva, with a price target of $8.30. The company’s shares closed last Thursday at $10.94.
According to TipRanks.com, Sharma is a 3-star analyst with an average return of
Currently, the analyst consensus on Valneva is a Moderate Buy with an average price target of $18.00.
See today’s best-performing stocks on TipRanks >>
Supernus Pharmaceuticals (SUPN)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Supernus Pharmaceuticals on February 24 and set a price target of $63.00. The company’s shares closed last Thursday at $55.75.
According to TipRanks.com, Kluska is a 5-star analyst with an average return of
Supernus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $62.17, an 11.8% upside from current levels. In a report issued on February 24, Bank of America Securities also maintained a Buy rating on the stock with a $65.00 price target.
